PDGFRB (P09619) variants and mutations
PDGFRB (also known as P09619) is a human protein-coding gene encoding a platelet-derived growth factor receptor beta protein. Its signaling supports pericytes, vascular smooth-muscle cells, and other mesenchymal lineages during growth and tissue repair. Oncogenic fusions drive myeloid neoplasms, while germline activating or loss-of-function variants can cause developmental and vascular disorders. This analysis covers 2,184 PDGFRB variants and mutations. Of these, 61% have computational variant effect predictions. Disease context includes Basal ganglia calcification, bilateral striopallidodentate calcinosis, and myofibromatosis, infantile, 1. Example PDGFRB variants include R2G, R2Q, and R2W.
Variant analysis overview
- Gene: PDGFRB
- Protein: P09619
- UniProt accession: P09619
- Organism: Homo sapiens
- Variants analyzed: 2184
- Variant scope: all variants
- Completed: 2026-08-18
Variant and mutation evidence
- Variant composition: 2,030 unspecified-consequence records; 1 stop lost; 80 synonymous variants; 49 missense variants; 13 frameshift variants; 4 in-frame deletions; 2 stop-gained variants; 2 splice-region variants; 3 substitution
- Prediction scores: 1,338 variants have prediction scores (61% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Basal ganglia calcification, bilateral striopallidodentate calcinosis, myofibromatosis, infantile, 1, infantile myofibromatosis, skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesi, acroosteolysis-keloid-like lesions-premature aging syndrome, hepatocellular carcinoma, gastrointestinal stromal tumor, chronic myelogenous leukemia, BCR-ABL1 positive, acute myeloid leukemia, neoplasm, renal cell carcinoma.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 6 domains; 2 binding sites; 27 post-translational modification sites.
- Structural context: 1,440 variants have structural context.
- PTM context: 38 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable PDGFRB variants
Examples include R2G, R2Q, R2W, L3F, L3H, L3P, L3V, P4A. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- R2G (p.Arg2Gly), ESP rs148272095, ExAC rs148272095, TOPMed rs148272095, gnomAD rs148272095, REVEL 0.03, CADD 10.30, Likely benign
- R2Q (p.Arg2Gln), rs372399976, ClinGen CA3508464, ClinVar RCV004503253, ClinVar RCV005220906, REVEL 0.02, CADD 1.66, Conflicting interpretations, Basal ganglia calcification, idiopathic, 4; Skeletal overgrowth-craniofacial dys
- R2W (p.Arg2Trp), rs148272095, ClinGen CA3508465, ClinVar RCV003797595, ClinVar RCV006449193, REVEL 0.06, CADD 12.20, Likely benign, Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesi
- L3F (p.Leu3Phe), ExAC rs757231368, TOPMed rs757231368, gnomAD rs757231368, REVEL 0.03, CADD 15.70, Uncertain significance, Inborn genetic diseases
- L3H (p.Leu3His), Ensembl rs2113914893
- L3P (p.Leu3Pro), Ensembl rs2113914893, REVEL 0.05, CADD 15.50
- L3V (p.Leu3Val), ExAC rs757231368, TOPMed rs757231368, gnomAD rs757231368
- P4A (p.Pro4Ala), Ensembl rs2113914882
- P4L (p.Pro4Leu), rs144923639, ClinGen CA3508461, ClinVar RCV003810031, ClinVar RCV005435309, REVEL 0.02, CADD 5.28, Benign, not specified; Basal ganglia calcification, idiopathic, 4; Infantile myofibromat
- P4Q (p.Pro4Gln), rs144923639, ClinGen CA3508462, ClinVar RCV003410425, ClinVar RCV006561581, REVEL 0.06, CADD 7.76, Conflicting interpretations, Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesi
- P4R (p.Pro4Arg), ESP rs144923639, ExAC rs144923639, TOPMed rs144923639, gnomAD rs144923639, Benign
- P4S (p.Pro4Ser), Ensembl rs2113914882
- P4T (p.Pro4Thr), NCI-TCGA Cosmic COSV1043, Variant assessed as somatic; moderate impact.
- G5A (p.Gly5Ala), gnomAD rs1431198340, REVEL 0.04, CADD 1.31
- G5C (p.Gly5Cys), Ensembl rs2113914853
- G5D (p.Gly5Asp), gnomAD rs1431198340, REVEL 0.03, CADD 8.87
- G5R (p.Gly5Arg), Ensembl rs2113914853
- G5S (p.Gly5Ser), Ensembl rs2113914853, REVEL 0.03, CADD 5.58
- G5V (p.Gly5Val), gnomAD rs1431198340, MetaLR 0.18, MetaSVM -0.89
- A6G (p.Ala6Gly), rs150173975, ClinGen CA361730880, ClinVar RCV002303198, 1000Genomes rs150173975, AlphaMissense 0.08, MetaLR 0.15, Uncertain significance, Infantile myofibromatosis; Acroosteolysis-keloid-like lesions-premature aging sy
- A6P (p.Ala6Pro), ExAC rs766578665, gnomAD rs766578665
- A6S (p.Ala6Ser), ExAC rs766578665, gnomAD rs766578665, MetaLR 0.20, MetaSVM -0.90
- A6T (p.Ala6Thr), ExAC rs766578665, gnomAD rs766578665, REVEL 0.04, CADD 0.87
- A6V (p.Ala6Val), rs150173975, ClinGen CA3508457, NCI-TCGA Cosmic COSV5580, ClinVar RCV002100466, REVEL 0.04, AlphaMissense 0.08, Likely benign, Acroosteolysis-keloid-like lesions-premature aging syndrome; Skeletal overgrowth
- M7I (p.Met7Ile), Ensembl rs2113914797, REVEL 0.05, CADD 8.67
- M7K (p.Met7Lys), gnomAD rs1432048735
- M7L (p.Met7Leu), Ensembl rs2113914811
- M7R (p.Met7Arg), gnomAD rs1432048735, REVEL 0.03, CADD 13.40
- M7V (p.Met7Val), Ensembl rs2113914811, MetaLR 0.12, MetaSVM -1.01
- P8A (p.Pro8Ala), rs1760652843, ClinGen CA361730826, ClinVar RCV003149489, TOPMed rs1760652843, AlphaMissense 0.08, MetaLR 0.18, Uncertain significance, not provided
- P8L (p.Pro8Leu), Ensembl rs2113914786
- P8Q (p.Pro8Gln), Ensembl rs2113914786
- P8R (p.Pro8Arg), Ensembl rs2113914786
- P8S (p.Pro8Ser), NCI-TCGA Cosmic COSV9994, TOPMed rs1760652843, Uncertain significance
- P8T (p.Pro8Thr), TOPMed rs1760652843, Uncertain significance
- A9P (p.Ala9Pro), ExAC rs748711817, gnomAD rs748711817, REVEL 0.20, CADD 22.00
- A9T (p.Ala9Thr), ExAC rs748711817, gnomAD rs748711817
- L10M (p.Leu10Met), Ensembl rs2113914753
- L10P (p.Leu10Pro), 1000Genomes rs576388049, ExAC rs576388049, gnomAD rs576388049, REVEL 0.33, CADD 8.75
- L10Q (p.Leu10Gln), 1000Genomes rs576388049, ExAC rs576388049, gnomAD rs576388049
- L10V (p.Leu10Val), Ensembl rs2113914753
- A11P (p.Ala11Pro), 1000Genomes rs199730626, ExAC rs199730626, gnomAD rs199730626, REVEL 0.20, CADD 13.20, Uncertain significance
- A11S (p.Ala11Ser), 1000Genomes rs199730626, ExAC rs199730626, gnomAD rs199730626, Uncertain significance
- A11T (p.Ala11Thr), rs199730626, ClinGen CA3508452, ClinVar RCV002970526, 1000Genomes rs199730626, REVEL 0.01, CADD 11.30, Uncertain significance, Inborn genetic diseases
- A11V (p.Ala11Val), gnomAD rs1465066628, MetaLR 0.16, MetaSVM -1.00
- L12F (p.Leu12Phe), ExAC rs746497331, gnomAD rs746497331, REVEL 0.06, CADD 13.50
- L12H (p.Leu12His), Ensembl rs2113914716
- L12I (p.Leu12Ile), ExAC rs746497331, gnomAD rs746497331
- L12P (p.Leu12Pro), Ensembl rs2113914716
- L12R (p.Leu12Arg), Ensembl rs2113914716
- L12V (p.Leu12Val), ExAC rs746497331, gnomAD rs746497331
- K13* (p.Lys13Ter), Ensembl rs2113914706
- K13N (p.Lys13Asn), Ensembl rs2113914702, MetaLR 0.15, MetaSVM -0.93
- G14V (p.Gly14Val), TOPMed rs1252598875, gnomAD rs1252598875, REVEL 0.26, CADD 33.00
- E15* (p.Glu15Ter), NCI-TCGA Cosmic COSV5580, Variant assessed as somatic; high impact.
- E15K (p.Glu15Lys), rs148853962, ClinGen CA3508423, ClinVar RCV001070780, ClinVar RCV004693584, REVEL 0.10, CADD 17.90, Uncertain significance, Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesi
- L17M (p.Leu17Met), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S20C (p.Ser20Cys), ExAC rs750698728, gnomAD rs750698728, REVEL 0.07, CADD 9.55
- S20P (p.Ser20Pro), ExAC rs758433037, gnomAD rs758433037, REVEL 0.11, CADD 7.49
- L21F (p.Leu21Phe), NCI-TCGA Cosmic COSV5580, Ensembl rs2113912885, REVEL 0.04, CADD 11.30, Variant assessed as somatic; moderate impact.
- L22R (p.Leu22Arg), gnomAD rs1238451735, REVEL 0.30, CADD 18.80
- L24F (p.Leu24Phe), rs762297182, ClinGen CA3508417, ClinVar RCV003361235, ClinVar RCV004763661, REVEL 0.06, CADD 10.30, Uncertain significance, not provided; Inborn genetic diseases
- P27L (p.Pro27Leu), Ensembl rs1323456502
- P27Q (p.Pro27Gln), Ensembl rs1323456502, MetaLR 0.13, MetaSVM -1.03
- P27S (p.Pro27Ser), gnomAD rs758514857, REVEL 0.04, CADD 11.80, Uncertain significance, Inborn genetic diseases
- I29F (p.Ile29Phe), rs17110944, ClinGen CA3508416, ClinVar RCV000551181, ClinVar RCV001573749, REVEL 0.02, CADD 0.87, Benign, Myofibromatosis, infantile, 1; not specified; Acroosteolysis-keloid-like lesions
- I29M (p.Ile29Met), TOPMed rs1760614395
- I29T (p.Ile29Thr), Ensembl rs1760614470, MetaLR 0.16, MetaSVM -1.01
- S30C (p.Ser30Cys), TOPMed rs561937933, REVEL 0.10, CADD 19.60
- Q31* (p.Gln31Ter), ExAC rs764493388, gnomAD rs764493388, CADD 33.00, Uncertain significance
- Q31E (p.Gln31Glu), NCI-TCGA Cosmic COSV5580, Variant assessed as somatic; moderate impact.
- Q31K (p.Gln31Lys), ExAC rs764493388, gnomAD rs764493388, REVEL 0.06, CADD 2.55, Uncertain significance, Infantile myofibromatosis; Basal ganglia calcification, idiopathic, 4; Skeletal
- G32D (p.Gly32Asp), rs368010583, ESP rs368010583, ExAC rs368010583, TOPMed rs368010583, AlphaMissense 0.08, MetaLR 0.31, Variant assessed as somatic; moderate impact.
- G32R (p.Gly32Arg), ExAC rs761286709, TOPMed rs761286709, gnomAD rs761286709, Uncertain significance
- G32S (p.Gly32Ser), rs761286709, ClinGen CA3508414, ClinVar RCV001773882, ClinVar RCV002540243, REVEL 0.09, CADD 11.20, Uncertain significance, Infantile myofibromatosis; Acroosteolysis-keloid-like lesions-premature aging sy
- L33P (p.Leu33Pro), Ensembl rs2113912805
- V35G (p.Val35Gly), Ensembl rs2113912786
- V35I (p.Val35Ile), rs568728923, ClinGen CA3508411, ClinVar RCV002655990, 1000Genomes rs568728923, REVEL 0.04, CADD 8.34, Likely benign, Inborn genetic diseases
- V35L (p.Val35Leu), 1000Genomes rs568728923, ExAC rs568728923, TOPMed rs568728923, gnomAD rs568728923, Likely benign
- T36I (p.Thr36Ile), ExAC rs774107509, TOPMed rs774107509, gnomAD rs774107509, REVEL 0.01, CADD 2.29
- T36S (p.Thr36Ser), gnomAD rs1159899108, REVEL 0.04, CADD 11.50
- P37A (p.Pro37Ala), rs748906060, ClinGen CA3508409, ClinVar RCV002290932, ExAC rs748906060, REVEL 0.39, CADD 24.80, Uncertain significance, not provided
- P37L (p.Pro37Leu), Ensembl rs2113912759, REVEL 0.47, CADD 25.80
- P37S (p.Pro37Ser), ExAC rs748906060, TOPMed rs748906060, gnomAD rs748906060, REVEL 0.42, CADD 25.40, Uncertain significance
- P38L (p.Pro38Leu), ExAC rs754766440, TOPMed rs754766440, gnomAD rs754766440, REVEL 0.07, CADD 15.90, Uncertain significance, Inborn genetic diseases
- P38R (p.Pro38Arg), NCI-TCGA Cosmic COSV5580, ExAC rs754766440, TOPMed rs754766440, gnomAD rs754766440, REVEL 0.04, CADD 14.10, Variant assessed as somatic; high impact.
- P38S (p.Pro38Ser), Ensembl rs1760612979
- G39A (p.Gly39Ala), Ensembl rs2113912717, REVEL 0.03, CADD 10.70
- G39R (p.Gly39Arg), ExAC rs750457698, gnomAD rs750457698, REVEL 0.12, CADD 22.50
- P40T (p.Pro40Thr), gnomAD rs1204706180, REVEL 0.02, CADD 18.40
- E41K (p.Glu41Lys), rs1021692167, ClinGen CA129070275, ClinVar RCV002747362, TOPMed rs1021692167, REVEL 0.24, CADD 26.50, Uncertain significance, Inborn genetic diseases
- L42F (p.Leu42Phe), gnomAD rs1760612434, REVEL 0.01, CADD 18.10
- L42H (p.Leu42His), Ensembl rs2113912688, REVEL 0.17, CADD 24.40
- L42P (p.Leu42Pro), Ensembl rs2113912688, Uncertain significance, PDGFRB-related disorder
- V43A (p.Val43Ala), rs778982886, ClinGen CA3508401, ClinVar RCV002873642, ExAC rs778982886, REVEL 0.24, CADD 23.90, Likely benign, Inborn genetic diseases
- V43L (p.Val43Leu), Ensembl rs2113912682
- L44F (p.Leu44Phe), TOPMed rs1239434481, gnomAD rs1239434481, REVEL 0.27, CADD 26.90, Uncertain significance, not provided
- L44V (p.Leu44Val), TOPMed rs1239434481, gnomAD rs1239434481, Uncertain significance
- N45S (p.Asn45Ser), ExAC rs757431440, gnomAD rs757431440, REVEL 0.07, CADD 18.30
- V46I (p.Val46Ile), rs2113912660, ClinGen CA361729342, ClinVar RCV003267330, REVEL 0.04, CADD 0.03, Likely benign, Inborn genetic diseases
- V46L (p.Val46Leu), Ensembl rs2113912660
- S48G (p.Ser48Gly), TOPMed rs1323411468, gnomAD rs1323411468, REVEL 0.15, CADD 26.00
- S48I (p.Ser48Ile), Ensembl rs2113912651, MetaLR 0.19, MetaSVM -0.71
- S48N (p.Ser48Asn), Ensembl rs2113912651, REVEL 0.20, CADD 25.40
- F50L (p.Phe50Leu), ExAC rs753583697, TOPMed rs753583697, gnomAD rs753583697, REVEL 0.05, CADD 3.04
- V51A (p.Val51Ala), Ensembl rs904364986
- V51F (p.Val51Phe), NCI-TCGA Cosmic COSV5580, NCI-TCGA Cosmic COSV5581, REVEL 0.08, CADD 17.70, Variant assessed as somatic; moderate impact.
- V51I (p.Val51Ile), rs761086433, ClinGen CA3508397, ClinVar RCV003457133, ClinVar RCV006368235, REVEL 0.04, CADD 10.60, Uncertain significance, not provided; Inborn genetic diseases; Skeletal overgrowth-craniofacial dysmorph
- V51L (p.Val51Leu), ExAC rs761086433, TOPMed rs761086433, gnomAD rs761086433, Uncertain significance
- L52Q (p.Leu52Gln), Ensembl rs1760611437, MetaLR 0.27, MetaSVM -0.65
- T53S (p.Thr53Ser), Ensembl rs2113912611, MetaLR 0.10, MetaSVM -1.03
- C54F (p.Cys54Phe), TOPMed rs1331996642, gnomAD rs1331996642
- C54Y (p.Cys54Tyr), TOPMed rs1331996642, gnomAD rs1331996642, MetaLR 0.79, MetaSVM 0.76
- S55L (p.Ser55Leu), rs147952898, ClinGen CA3508396, ClinVar RCV000523080, ClinVar RCV002525179, REVEL 0.14, CADD 13.60, Conflicting interpretations, Inborn genetic diseases; not provided; Acroosteolysis-keloid-like lesions-premat
- G56C (p.Gly56Cys), gnomAD rs1386589670, REVEL 0.32, CADD 25.30
- G56D (p.Gly56Asp), TOPMed rs1760610944
- G56R (p.Gly56Arg), gnomAD rs1386589670
- A58P (p.Ala58Pro), Ensembl rs2113912565
- A58S (p.Ala58Ser), Ensembl rs2113912565, MetaLR 0.03, MetaSVM -0.98
- A58T (p.Ala58Thr), Ensembl rs2113912565, REVEL 0.08, CADD 19.00
- P59A (p.Pro59Ala), ESP rs144954868
- P59L (p.Pro59Leu), rs202213873, ClinGen CA3508391, ClinVar RCV001223591, ClinVar RCV002563647, REVEL 0.13, CADD 24.30, Conflicting interpretations, Infantile myofibromatosis; Skeletal overgrowth-craniofacial dysmorphism-hyperela
- P59R (p.Pro59Arg), 1000Genomes rs202213873, ESP rs202213873, ExAC rs202213873, TOPMed rs202213873, REVEL 0.18, CADD 23.30, Uncertain significance, Basal ganglia calcification, idiopathic, 4; Skeletal overgrowth-craniofacial dys
- P59S (p.Pro59Ser), ESP rs144954868, REVEL 0.09, CADD 20.30
- V60G (p.Val60Gly), Ensembl rs2113912540, MetaLR 0.21, MetaSVM -0.65
- V60L (p.Val60Leu), gnomAD rs1478236512, REVEL 0.07, CADD 17.80
- V61E (p.Val61Glu), Ensembl rs2113912525
- V61L (p.Val61Leu), gnomAD rs1372232728, Likely benign, not provided
- W62* (p.Trp62Ter), NCI-TCGA Cosmic COSV5580, Ensembl rs2113912520, Variant assessed as somatic; high impact.
- W62C (p.Trp62Cys), Ensembl rs2113912520, MetaLR 0.84, MetaSVM 0.87
- E63G (p.Glu63Gly), Ensembl rs1301329768, MetaLR 0.04, MetaSVM -1.10
- E63K (p.Glu63Lys), NCI-TCGA Cosmic COSV5580, REVEL 0.04, CADD 20.30, Variant assessed as somatic; moderate impact.
- R64G (p.Arg64Gly), 1000Genomes rs367993439, ESP rs367993439, ExAC rs367993439, TOPMed rs367993439
- R64L (p.Arg64Leu), TOPMed rs1244128395, gnomAD rs1244128395, MetaLR 0.04, MetaSVM -1.07, Uncertain significance
- R64Q (p.Arg64Gln), rs1244128395, ClinGen CA361728954, ClinVar RCV003786743, TOPMed rs1244128395, REVEL 0.03, CADD 19.80, Uncertain significance, Acroosteolysis-keloid-like lesions-premature aging syndrome; Basal ganglia calci
- R64W (p.Arg64Trp), 1000Genomes rs367993439, ESP rs367993439, ExAC rs367993439, TOPMed rs367993439, REVEL 0.17, CADD 23.80, Uncertain significance, Basal ganglia calcification, idiopathic, 4; Infantile myofibromatosis; Acroosteo
- M65I (p.Met65Ile), Ensembl rs1041079383
- M65R (p.Met65Arg), Ensembl rs2113912497, MetaLR 0.03, MetaSVM -1.00
- S66F (p.Ser66Phe), TOPMed rs1277924406, gnomAD rs1277924406, REVEL 0.12, CADD 23.20
- S66P (p.Ser66Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S66T (p.Ser66Thr), ExAC rs747916560, gnomAD rs747916560, REVEL 0.02, CADD 14.50
- Q67H (p.Gln67His), Ensembl rs2113912470
- Q67P (p.Gln67Pro), ExAC rs776609724, gnomAD rs776609724, REVEL 0.12, CADD 22.20
- Q67R (p.Gln67Arg), ExAC rs776609724, gnomAD rs776609724
- E68D (p.Glu68Asp), ExAC rs766277403, gnomAD rs766277403, REVEL 0.01, CADD 7.55
- E68K (p.Glu68Lys), TOPMed rs1760609426, gnomAD rs1760609426, REVEL 0.05, CADD 7.73
- P69S (p.Pro69Ser), Ensembl rs2113912451, MetaLR 0.12, MetaSVM -0.99
- P70R (p.Pro70Arg), ExAC rs746904891, gnomAD rs746904891, REVEL 0.08, CADD 0.01
- Q71K (p.Gln71Lys), Ensembl rs1404594782
- Q71R (p.Gln71Arg), ExAC rs778879949, TOPMed rs778879949, gnomAD rs778879949, REVEL 0.09, CADD 16.80, Uncertain significance, Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesi
- M73K (p.Met73Lys), Ensembl rs2113912405
- M73L (p.Met73Leu), TOPMed rs1230244085
- M73R (p.Met73Arg), Ensembl rs2113912405, MetaLR 0.01, MetaSVM -0.99
- M73V (p.Met73Val), TOPMed rs1230244085, REVEL 0.03, CADD 0.15, Likely benign, Infantile myofibromatosis; Basal ganglia calcification, idiopathic, 4; Skeletal
- A74G (p.Ala74Gly), Ensembl rs2113912393
- A74T (p.Ala74Thr), TOPMed rs1760608643
- A74V (p.Ala74Val), NCI-TCGA Cosmic COSV9994, Ensembl rs2113912393, MetaLR 0.03, MetaSVM -1.03, Variant assessed as somatic; moderate impact.
- A76D (p.Ala76Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A76S (p.Ala76Ser), gnomAD rs1346227937, MetaLR 0.03, MetaSVM -1.00
- A76T (p.Ala76Thr), gnomAD rs1346227937, REVEL 0.01, CADD 6.18
- Q77L (p.Gln77Leu), TOPMed rs1269978839, gnomAD rs1269978839, REVEL 0.10, CADD 19.90
- Q77P (p.Gln77Pro), TOPMed rs1269978839, gnomAD rs1269978839, REVEL 0.06, CADD 19.70
- D78V (p.Asp78Val), gnomAD rs1436552710, REVEL 0.27, CADD 24.10
- D78Y (p.Asp78Tyr), NCI-TCGA Cosmic COSV5580, Ensembl rs2113912378, Variant assessed as somatic; moderate impact.
- G79A (p.Gly79Ala), gnomAD rs1224840287, REVEL 0.22, CADD 22.10
- G79D (p.Gly79Asp), gnomAD rs1224840287
- G79S (p.Gly79Ser), TOPMed rs1760607800
- G79V (p.Gly79Val), gnomAD rs1224840287, MetaLR 0.42, MetaSVM -0.11
- T80I (p.Thr80Ile), TOPMed rs1760607501, REVEL 0.04, CADD 6.68, Uncertain significance, not provided
- T80P (p.Thr80Pro), Ensembl rs2113912343
- T80S (p.Thr80Ser), Ensembl rs2113912343, MetaLR 0.07, MetaSVM -1.05
- F81I (p.Phe81Ile), rs2113912334, ClinGen CA361728392, ClinVar RCV001764816, Ensembl rs2113912334, AlphaMissense 0.33, MetaLR 0.17, Uncertain significance, not provided
- F81L (p.Phe81Leu), Ensembl rs1580810983, MetaLR 0.18, MetaSVM -0.82
- S82C (p.Ser82Cys), gnomAD rs1297813606
- S82F (p.Ser82Phe), gnomAD rs1297813606, REVEL 0.06, CADD 13.60
- S82T (p.Ser82Thr), Ensembl rs2113912324
- S83I (p.Ser83Ile), Ensembl rs2113912313
- S83T (p.Ser83Thr), NCI-TCGA TCGA novel, MetaLR 0.29, MetaSVM -0.67, Variant assessed as somatic; moderate impact.
- V84A (p.Val84Ala), rs2113912296, ClinGen CA361728261, ClinVar RCV001758787, Ensembl rs2113912296, REVEL 0.03, CADD 5.00, Uncertain significance, not provided
- V84E (p.Val84Glu), Ensembl rs2113912296, Uncertain significance, Inborn genetic diseases
Public PDGFRB analysis runs
- PDGFRB analysis run — PDGFRB (2,184 variants) — completed 2026-08-18